ZA9010332B - Method of reducing or preventing adverse effect of steroid therapy and compositions therefor - Google Patents

Method of reducing or preventing adverse effect of steroid therapy and compositions therefor

Info

Publication number
ZA9010332B
ZA9010332B ZA9010332A ZA9010332A ZA9010332B ZA 9010332 B ZA9010332 B ZA 9010332B ZA 9010332 A ZA9010332 A ZA 9010332A ZA 9010332 A ZA9010332 A ZA 9010332A ZA 9010332 B ZA9010332 B ZA 9010332B
Authority
ZA
South Africa
Prior art keywords
reducing
adverse effect
steroid therapy
preventing adverse
compositions therefor
Prior art date
Application number
ZA9010332A
Other languages
English (en)
Inventor
Ronald Lee Goldberg
Lee Goldberg Ronald
Original Assignee
Ciba Geigy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy filed Critical Ciba Geigy
Publication of ZA9010332B publication Critical patent/ZA9010332B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
ZA9010332A 1989-12-22 1990-12-12 Method of reducing or preventing adverse effect of steroid therapy and compositions therefor ZA9010332B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45521589A 1989-12-22 1989-12-22

Publications (1)

Publication Number Publication Date
ZA9010332B true ZA9010332B (en) 1991-08-28

Family

ID=23807878

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9010332A ZA9010332B (en) 1989-12-22 1990-12-12 Method of reducing or preventing adverse effect of steroid therapy and compositions therefor

Country Status (14)

Country Link
EP (1) EP0434625B1 (de)
JP (1) JP2934023B2 (de)
KR (1) KR100191381B1 (de)
AT (1) ATE121296T1 (de)
AU (1) AU641966B2 (de)
CA (1) CA2032859C (de)
DE (1) DE69018799T2 (de)
DK (1) DK0434625T3 (de)
ES (1) ES2071080T3 (de)
GR (1) GR3015900T3 (de)
IE (1) IE67510B1 (de)
IL (1) IL96711A (de)
NZ (1) NZ236614A (de)
ZA (1) ZA9010332B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128320A (en) * 1990-01-18 1992-07-07 Genentech, Inc. Method of restoring normal growth, weight gain or lean body mass in patients with glucocorticoid excess by administering igf-i
TW267102B (de) 1992-03-13 1996-01-01 Ciba Geigy
US5407913A (en) * 1992-12-03 1995-04-18 Celtrix Pharmaceuticals, Inc. Method and composition for systemic treatment of tissue injury
JPH10504971A (ja) * 1994-09-08 1998-05-19 カイロン コーポレイション インスリン様増殖因子の改善された生産方法
US5712249A (en) * 1994-09-08 1998-01-27 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
AU7271996A (en) * 1995-10-23 1997-05-15 Queen's University At Kingston Method and pharmaceutical composition for chondrostimulation with a prostaglandin (e.g. misoprostol) and tgf-beta, optionally in combination with igf-1
CA2265972A1 (en) * 1996-09-16 1998-03-26 Philip D. Acott Use of igf-i for the treatment of polycystic kidney disease and related indications
US6015786A (en) 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
US6514937B1 (en) 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
AU3548999A (en) 1998-04-03 1999-10-25 Chiron Corporation Use of igfi for treating articular cartilage disorders
PT1141014E (pt) 1999-01-06 2005-04-29 Genentech Inc Variante mutante do factor de crescimento semelhante a insulina (igf-i)
WO2001087323A2 (en) 2000-05-16 2001-11-22 Genentech, Inc. Method for treating cartilage disorders
EP1917039A4 (de) 2005-08-01 2011-01-19 Genera Istrazivanja D O O Verfahren und zusammensetzungen zur regeneration von gelenkknorpel

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE60517B1 (en) * 1986-11-14 1994-07-27 Inst Molecular Biology Inc Wound healing and bone regeneration
SE8703625D0 (sv) * 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
US4983581A (en) * 1988-05-20 1991-01-08 Institute Of Molecular Biology, Inc. Wound healing composition of IGF-I and TGF-β

Also Published As

Publication number Publication date
IE67510B1 (en) 1996-04-03
AU6824790A (en) 1991-06-27
AU641966B2 (en) 1993-10-07
CA2032859C (en) 2007-09-17
JPH04210648A (ja) 1992-07-31
EP0434625A3 (en) 1991-10-02
IL96711A0 (en) 1991-09-16
EP0434625A2 (de) 1991-06-26
GR3015900T3 (en) 1995-07-31
CA2032859A1 (en) 1991-06-23
IE904684A1 (en) 1991-07-17
KR100191381B1 (ko) 1999-06-15
IL96711A (en) 1996-01-19
KR910011279A (ko) 1991-08-07
NZ236614A (en) 1993-10-26
JP2934023B2 (ja) 1999-08-16
DE69018799D1 (de) 1995-05-24
ATE121296T1 (de) 1995-05-15
ES2071080T3 (es) 1995-06-16
DE69018799T2 (de) 1995-09-21
DK0434625T3 (da) 1995-06-26
EP0434625B1 (de) 1995-04-19

Similar Documents

Publication Publication Date Title
IL96711A0 (en) Method of reducing or preventing adverse effect of steroid therapy and compositions therefor
AU6853290A (en) Composition and method for the treatment of osteoporosis in mammals
GR3032844T3 (en) Prevention and treatment of peripheral neuropathy.
ZA945249B (en) Parathyrold hormone and raloxifene for increasing bone mass
CA2108770A1 (en) Bmp-9 compositions
AU4861493A (en) Clear leave-on treatment composition and method
EP0455422A3 (en) Method of treating or preventing baldness with compositions containing fibroblast growth factor
IL115405A0 (en) Compositions and methods for treating mast-cell mediated conditions
ATE109793T1 (de) Lineare und zyklische analoge von alpha-msh- fragmenten mit ausserordentlicher wirkung.
IL102344A0 (en) Method of preventing and treating chemotherapy-induced alopecia
IL105217A0 (en) Method and composition for treating acne
AU1888692A (en) Composition and method for treating tumors
AU9087591A (en) Composition and method for treating metal
EP0457848A4 (en) Treatment of pulmonary dysfunction and ventilator dependency with growth hormone
AU2434992A (en) Methods and compositions for treating sunburns
GB9301720D0 (en) Method and compositions for treating anoestrus
MX9408106A (es) Metodo y composicion para el tratamiento de hepatitis autoinmune.
UA7949A (uk) Спосіб обробки насіння
CS275008B2 (en) 2 alpha,3 alpha-dihydroxy-17 beta-(2-methyl-butyryloxy) -7-oxo-b-homo-androstane-6-on and method of its preparation
AU6059698A (en) Methods for treatment with dimercaptosuccinic acid (DMSA)